

Literaturquellen

1. Allen NA, Zagarins SE, Feinberg RG, Welch G. *Treating psychological insulin resistance in type 2 diabetes*. *J Clin Transl Endocrinol* 2017; 7: 1–6. Epub 2017/10/27. doi: 10.1016/j.jcte.2016.11.005. PubMed PMID: 29067243; PubMed Central PMCID: PMC5651283.
2. American Diabetes Association. *Glycemic Targets: Standards of Medical Care in Diabetes – 2021*. *Diabetes Care* 2021; 44(Supplement 1): S73–S84.
3. Arnolds S, Heise T, Flacke F, Sieber J. *Common standards of basal insulin titration in type 2 diabetes*. *J Diabetes Sci Technol* 2013; 7: 771–788.
4. Bajaj HS, Venn K, Ye C, Aronson R. *Randomized trial of long-acting insulin glargine titration web tool (LTHome) versus enhanced usual therapy of glargine titration (INNOVATE Trial)*. *Diabetes Technol Ther* 2016; 18: 1–6.
5. Balogh EG, Perez-Nieves M, Cao D, Hadjiyianni II, Ashraf N, Desai U *et al*. *Key Strategies for Overcoming Psychological Insulin Resistance in Adults with Type 2 Diabetes: The UK Subgroup in the EMOTION Study*. *Diabetes Ther* 2020; 11(8): 1735–44. Epub 2020/06/21. doi: 10.1007/s13300-020-00856-4. PubMed PMID: 32562245; PubMed Central PMCID: PMC7376995.
6. Barag SH. *Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence*. *J Am Osteopath Assoc* 2011; 111(Suppl. 5): S13–S16.
7. Berard L, Bonnemaire M, Mical M, Edelman S. *Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey*. *Diabetes Obes Metab* 2018; 20(2): 301–308.
8. Blak BT, Smith HT, Hards M, Maguire A, Gimeno V. *A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care*. *Diabet Med* 2012; 29(8): e191–8. Epub 2012/04/18. doi: 10.1111/j.1464-5491.2012.03694.x. PubMed PMID: 22507537.
9. Blonde L, Merilainen M, Karve V, Raskin P, Group TS. *Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE study*. *Diabetes Obes Metab* 2009; 11(6): 623–31. Epub 2009/06/12. doi: 10.1111/j.1463-1326.2009.01060.x. PubMed PMID: 19515182.
10. Bolli GB, Riddle MC, Bergenstal RM *et al*. *New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)*. *Diabetes Obes Metab* 2015; 17(4): 386–394.
11. Bonadonna RC, Giaccari A, Buzzetti R *et al*. *Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study*. *Diabetes Metab Res Rev* 2020; 36(6): e3304.
12. Brzan PP, Rotman E, Pajnikhar M, Klanjssek P. *Mobile Applications for Control and Self Management of Diabetes: A Systematic Review*. *J Med Syst* 2016; 40(9): 210. Epub 2016/08/16. doi: 10.1007/s10916-016-0564-8. PubMed PMID: 27520615.
13. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), (AWMF) AdWMF: Nationale VersorgungsLeitlinie Typ-2-Diabetes – Langfassung, 2. Auflage. Konsultationsfassung, 2020 [01/2021]. Available from: www.diabetes.versorgungsleitlinien.de.
14. Chun J, Strong J and Urquhart S. *Insulin Initiation and Titration in Patients With Type 2 Diabetes*. *Diabetes Spectrum* 2019; 32(2): 104–111.
15. Cramer JA. *A systematic review of adherence with medications for diabetes*. *Diabetes Care* 2004; 27(5): 1218–24. Epub 2004/04/28. doi: 10.2337/diacare.27.5.1218. PubMed PMID: 15111553.
16. Cui M, Wu X, Mao J, Wang X, Nie M. *T2DM Self-Management via Smartphone Applications: A Systematic Review and Meta-Analysis*. *PLoS One* 2016; 11(11): e0166718. Epub 2016/11/20. doi: 10.1371/journal.pone.0166718. PubMed PMID: 27861583; PubMed Central PMCID: PMC5115794.
17. Dailey G, Aurand L, Stewart J, Ameer B, Zhou R. *Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naïve patients with type 2 diabetes mellitus*. *J Diabetes* 2014; 6: 176–183.
18. Davies M, Storms F, Shuttler S, Bianchi-Biscay M, Gomis R, Group AS. *Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine*. *Diabetes Care* 2005; 28(6): 1282–8. Epub 2005/05/28. doi: 10.2337/diacare.28.6.1282. PubMed PMID: 15920040.
19. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. *Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review*. *Diabet Med* 2013; 30(5): 512–24. Epub 2013/01/18. doi: 10.1111/dme.12128. PubMed PMID: 23323988.
20. Dornhorst A, Luddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ *et al*. *Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study*. *Int J Clin Pract* 2008; 62(4): 659–65. Epub 2008/03/08. doi: 10.1111/j.1742-1241.2008.01715.x. PubMed PMID: 18324957.
21. Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ *et al*. *Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study*. *International Journal of Clinical Practice* 2008; 62(4): 659–65. doi: <https://doi.org/10.1111/j.1742-1241.2008.01715.x>.
22. Edelman S *et al*. *Device-Supported vs. Routine Titration of Insulin Glargine 300 U/mL (Gla-300) in T2DM: Efficacy and Safety*. ADA 77th Scientific Sessions 2017, late breaking poster 131-LB.
23. Escalada J, Bonnet F, Wu J, Bonnemaire M, Gupta S, Cambron-Melloth JM *et al*. *Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/ Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study*. *Adv Ther* 2020; 37(9): 3863–77. Epub 2020/07/19. doi: 10.1007/s12325-020-01436-5. PubMed PMID: 32681460; PubMed Central PMCID: PMC7444406.
24. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI *et al*. *CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY*. *Endocrine Practice* 2020; 26(1): 107–39. doi: 10.4158/cs-2019-0472. PubMed PMID: 32022600.
25. Garg SK, Admane K, Freemantle N *et al*. *Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study*. *Endocr Pract* 2015; 21: 143–157.
26. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. *A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study*. *Diabet Med*. 2006; 23(7): 736–742.
27. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. *Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes*. *Diabetes Care* 2013; 36: 2536–2542.
28. Greenwood DA, Gee PM, Fatkin KJ, Peoples M. *A Systematic Review of Reviews Evaluating Technology-Enabled Diabetes Self-Management Education and Support*. *J Diabetes Sci Technol* 2017; 11(5): 1015–27. Epub 2017/06/01. doi: 10.1177/1932296817713506. PubMed PMID: 28560898; PubMed Central PMCID: PMC5951000.
29. Guzmán JR, Lyra R, Aguilar-Salinas CA, Cavalcanti S, Escañó F, Tambasia M *et al*. *Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries*. *Latin American Diabetes Association. Revista panamericana de salud publica = Pan American journal of public health* 2010; 28(6): 463–71. Epub 2011/02/11. doi: 10.1590/s1020-49892010001200008. PubMed PMID: 21308173.
30. Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Morschel L. *Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial*. *Lancet Diabetes Endocrinol* 2019; 7(3): 179–88. Epub 2019/01/27. doi: 10.1016/S2213-8587(18)30372-3. PubMed PMID: 30679095.

31. Hermanns N *et al.* *Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors.* *Diabet Med*, 2005; 22(3): 293-300.
32. Hermanns N, Mahr M, Kulzer B, Skovlund SE, Haak T. *Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study.* *Health Qual Life Outcomes* 2010; 8: 113. Epub 2010/10/06. doi: 10.1186/1477-7525-8-113. PubMed PMID: 20920319; PubMed Central PMCID: PMCPCMC2959097.
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. *10-year follow-up of intensive glucose control in type 2 diabetes.* *N Engl J Med* 2008; 359(15): 1577-1589.
34. Holmes-Truscott E, Skinner TC, Pouwer F, Speight J. *Negative appraisals of insulin therapy are common among adults with Type 2 diabetes using insulin: Results from Diabetes MILES – Australia cross-sectional survey.* *Diabet Med* 2015; 32(10): 1297-303. Epub 2015/02/17. doi: 10.1111/dme.12729. PubMed PMID: 25683652.
35. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M *et al.* *Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).* *Diabetes Care* 2012; 35(6): 1364-79. Epub 2012/04/21. doi: 10.2337/dc12-0413. PubMed PMID: 22517736; PubMed Central PMCID: PMCPCMC3357214.
36. Jain SM, Seshadri K, Unnikrishnan AG, Chawla M, Kaira P, Vipin VP *et al.* *Best Practices and Tools for Titrating Basal Insulins: Expert Opinion from an Indian Panel via the Modified Delphi Consensus Method.* *Diabetes therapy: research, treatment and education of diabetes and related disorders*. 2020; 11(3): 621-32. Epub 2020/02/03. doi: 10.1007/s13300-020-00770-9. PubMed PMID: 32009224.
37. Janes R, Titchener J, Pere J, Pere R, Senior J. *Understanding barriers to glycaemic control from the patient's perspective.* *J Prim Health Care* 2013; 5: 114-122.
38. Janka HU, Plewe G, Busch K. *Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.* *J Am Geriatr Soc* 2007; 55(2): 182-8. Epub 2007/02/17. doi: 10.1111/j.1532-5415.2007.01043.x. PubMed PMID: 17302653.
39. Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, Group SS. *Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.* *Diabetes Obes Metab* 2012; 14(7): 654-61. Epub 2012/03/27. doi: 10.1111/j.1463-1326.2012.01602.x. PubMed PMID: 22443213.
40. Khunti K *et al.* *Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.* *Diabetes, Obesity & Metabolism* 2016; 18(4): 401-409.
41. Khunti K, Millar-Jones D. *Clinical inertia to insulin initiation and intensification in the UK: A focused literature review.* *Prim Care Diabetes* 2017; 11(1): 3-12. Epub 2016/10/12. doi: 10.1016/j.pcd.2016.09.003. PubMed PMID: 27727005.
42. Khunti K, Giorgino F, Berard L, Mauricio D, Harris SB. *The importance of the initial period of basal insulin titration in people with diabetes.* *Diabetes Obes Metab* 2020; 22(5): 722-733.
43. Kostev K, Dippel FW, Rathmann W. *Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.* *Prim Care Diabetes* 2016; 10(2): 142-7. Epub 2015/09/02. doi: 10.1016/j.pcd.2015.08.001. PubMed PMID: 26324105.
44. Kostev K, Pscherer S, Rist R, Busch S, Scheerer MF. *Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.* *J Diabetes Sci Technol* 2017; 11(3): 590-6. Epub 2017/03/17. doi: 10.1177/1932296816688011. PubMed PMID: 28300454; PubMed Central PMCID: PMCPCMC5505432.
45. Landgraf R, Aberle J, Birkenfeld A, Gallwitz B, Kellerer M, Klein H, Müller-Wieland D, Nauck M, Reuter HM, Siegel E. *Therapie des Typ-2-Diabetes.* *Diabetologie und Stoffwechsel* 2019; 14 (Suppl 2): S167-87.
46. Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein HH *et al.* *Therapie des Typ-2-Diabetes.* *Diabetologie und Stoffwechsel* 2020; 15(S 01): S65-S92. doi: 10.1055/a-1193-3793.
47. Liebl A, Wilhelm B, Kaiser M. *[Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].* *MMW Fortschr Med* 2012; 154 Suppl 4: 102-9. Epub 2013/01/19. PubMed PMID: 23326928.
48. Ligthelm RJ. *Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.* *Prim Care Diabetes* 2009; 3(2): 97-102. Epub 2009/03/17. doi: 10.1016/j.pcd.2009.01.003. PubMed PMID: 19285933.
49. Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L *et al.* *Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.* *Diabetes Obes Metab* 2017; 19(8): 1155-64. Epub 2017/03/03. doi: 10.1111/dom.12927. PubMed PMID: 28251792; PubMed Central PMCID: PMCPCMC5573947.
50. Meneghini L, Koenen C, Weng W, Selam J-L. *The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes: results of the randomized, controlled PREDICTIVE™ 303 study.* *Diabetes Obes Metab* 2007; 9: 902-91.
51. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. *Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.* *Diabetes Obes Metab* 2007; 9(3): 418-27. Epub 2007/03/30. doi: 10.1111/j.1463-1326.2006.00674.x. PubMed PMID: 17391170.
52. Mocarski M, Yeaw J, Divino V, DeKoven M, Guerrero G, Langer J *et al.* *Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.* *J Manag Care Spec Pharm* 2018; 24(4): 390-400. Epub 2018/02/07. doi: 10.18553/jmcp.2017.17218. PubMed PMID: 29406841.
53. Modi K, Jha S, Manju P, Raskar V, Mittal D, Ghosh R *et al.* *Digital-Tool-Supported Basal Insulin (BI) Titration: Real-World Effectiveness of My Dose Coach in India.* *Jahrestagung der American Diabetes Association* 2019.
54. National Institute for Health and Care Excellence (NICE). *Type 2 diabetes in adults: management* 2015 [01/2020]. Available from: <https://www.nice.org.uk/guidance/ng28>.
55. Ng CJ, Lai PS, Lee YK, Azmi SA, Teo CH. *Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review.* *Int J Clin Pract* 2015; 69: 1050-1070.
56. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. *Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes.* *Cardiovasc Diabetol* 2015; 14: 100. Epub 2015/08/08. doi: 10.1186/s12933-015-0260-x. PubMed PMID: 26249018; PubMed Central PMCID: PMCPCMC4528846.
57. Peeples M, Greenwood DA, Gee PM. *Technology-Enabled Diabetes Self-Management Education & Support.* *Diabetes Technology Meeting*; Nov 2-4 2017.
58. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. *Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study.* *Diabet Med* 2012; 29(5): 682-9. Epub 2012/02/09. doi: 10.1111/j.1464-5491.2012.03605.x. PubMed PMID: 22313123; PubMed Central PMCID: PMCPCMC3433794.
59. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR *et al.* *Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.* *Diabetes Care* 2005; 28(11): 2673-9. Epub 2005/10/27. doi: 10.2337/diacare.28.11.2673. PubMed PMID: 16249538.

60. Pfohl M, Jornayvaz FR, Fritsche A, Pscherer S, Anderten H, Pegelow K *et al.* Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes after failure of oral therapy in a real-world setting. *Diabetes Obes Metab* 2020; 22(5): 759–66. Epub 2020/01/07. doi: 10.1111/dom.13952. PubMed PMID: 31903680; PubMed Central PMCID: PMCPCMC7187365.
61. Pfützner A, Stratmann B, Funke K *et al.* Real-world data collection regarding titration algorithms for insulin glargine in patients with type 2 diabetes mellitus. *J Diabetes Sci Technol* 2016; 10: 1122–1129.
62. Philis-Tsimikas A, Brod M, Niemeier M, Ocampo Francisco AM, Rothman J. *Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: Once Simple Use)*. *Adv Ther* 2013; 30: 607–622.
63. Polinski JM, Smith BF, Curtis BH, Seeger JD, Choudhry NK, Connolly JG *et al.* Barriers to insulin progression among patients with type 2 diabetes: a systematic review. *Diabetes Educ* 2013; 39(1): 53–65. Epub 2012/11/30. doi: 10.1177/0145721712467696. PubMed PMID: 23192599.
64. Polonsky WH and Jackson RA. *What's So Tough About Taking Insulin? Addressing the Problem of Psychological Insulin Resistance in Type 2 Diabetes*. *Clinical Diabetes* 2004; 22(3): 147–150.
65. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. *Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem*. *Diabetes Care* 2005; 28(10): 2543–5. Epub 2005/09/28. doi: 10.2337/diacare.28.10.2543. PubMed PMID: 16186296.
66. Polonsky WH. *Psychological insulin resistance: the patient perspective*. *Diabetes Educ* 2007. 33 Suppl 7: 241S–244S.
67. Polonsky WH *et al.* Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. *Curr Med Res Opin* 2011; 27(6): 1169–1174.
68. Polonsky WH, Fisher L, Hessler D, Stuckey H, Snoek FJ, Tang T *et al.* Identifying solutions to psychological insulin resistance: An international study. *J Diabetes Complications* 2019; 33(4): 307–14. Epub 2019/02/03. doi: 10.1016/j.jdiacomp.2019.01.001. PubMed PMID: 30709604.
69. Pscherer S, Anderten H, Pfohl M, Fritsche A, Borck A, Pegelow K *et al.* Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study. *Acta Diabetol* 2020; 57(1): 89–99. Epub 2019/07/26. doi: 10.1007/s00592-019-01383-w. PubMed PMID: 31342163.
70. Ratanawongsa N, Crosson JC, Schillinger D, Karter AJ, Saha CK, Marrero DG. *Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project*. *Diabetes Educ* 2012; 38(1): 94–100. Epub 2012/01/10. doi: 10.1177/0145721711432649. PubMed PMID: 22222513; PubMed Central PMCID: PMCPCMC3557962.
71. Riddle MC, Bolli GB, Ziemien M *et al.* New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). *Diabetes Care* 2014; 37(10): 2755–2762.
72. Russell-Jones D, Pouwer F, Khunti K. *Identification of barriers to insulin therapy and approaches to overcoming them*. *Diabetes Obes Metab* 2018; 20(3): 488–96. Epub 2017/10/21. doi: 10.1111/dom.13132. PubMed PMID: 29053215; PubMed Central PMCID: PMCPCMC5836933.
73. Russell-Jones D, Dauchy A, Delgado E *et al.* Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes. *Diabetes Obes Metab* 2019; 21(7): 1615–1624.
74. Sandler CN, McDonnell ME. *The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk*. *Cleveland Clinic Journal of Medicine* 2016; 83(5 Suppl 1): S4–S10.
75. Sanofi-Aventis Deutschland GmbH. *My Dose Coach clinical portal user guide*. 2019.
76. Santos OMC, Facio R, Gonzalez D, Romero-Ibarguengoitia M, Perez H. *Effectiveness of My Dose Coach in achieving Self-Measured Plasma Glucose goal and improving Well Being index in patients with type 3 diabetes in Mexico*. *International Conference on Advanced Technologies & Treatments for Diabetes 2020*, Abstract 430.
77. Santos OMC, Facio R, Gonzalez D, Tamez H, Ibarguengoitia M. *Real world effectiveness of Digital-tool-supported basal insulin titration, My Dose Coach, in reaching fasting blood glucose goal and A1c reduction in Mexico*. *International Conference on Advanced Technologies & Treatments for Diabetes 2020*, Abstract 100.
78. Seufert J, Fritsche A, Pscherer S, Anderten H, Pegelow K, Pfohl M. *Erfolg einer Umstellung auf Insulin glargin 300 E/ml (Gla-300) nach Versagen einer basalunterstützten oralen Therapie (BOT) bei Typ-2-Diabetespatienten – 6-Monats-Ergebnisse der TOP-2-Studie*. *Diabetes Kongress 2018 – 53. Jahrestagung der DDG*; Berlin 2018.
79. Seufert J, Pegelow K, Bramlage P. *Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study*. *Vasc Health Risk Manag* 2013; 9: 711–7. Epub 2013/11/22. doi: 10.2147/VHRM.S54362. PubMed PMID: 24259985; PubMed Central PMCID: PMCPCMC3833837.
80. Shah S. *APP-based Approach to Basal Insulin Titration: Initial Results of the MyDoseCoach Pilot in India*. *International Diabetes Federation – Western Pacific Region Congress* 2018.
81. Siegmund T, Pfohl M, Forst T, Pscherer S, Bramlage P, Foersch J *et al.* Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients. *Diabetes Metab Syndr* 2017; 11(1): 51–7. Epub 2016/09/01. doi: 10.1016/j.dsx.2016.08.006. PubMed PMID: 27578616.
82. Stratton IM, Adler AI, Neil HA *et al.* Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000; 321(7258): 405–41.
83. Unnikrishnan A, Farishta F, Gupta P, Ghosh R, Zhou F, Summers M *et al.* Digital-tool-supported basal insulin titration: real-world effectiveness of My Dose Coach™ (MDC) in people with type 2 diabetes (T2D) in India *International Conference on Advanced Technologies & Treatments for Diabetes 2020*, Abstract 563.
84. Wang HF, Yeh MC. *Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review*. *J Adv Nurs* 2012; 68(4): 743–57. Epub 2011/11/05. doi: 10.1111/j.1365-2648.2011.05853.x. PubMed PMID: 22050365.
85. Williams R. *Breaking down barriers to insulin management in primary care*. *Prim Care Diabetes* 2010; 4(Suppl. 1): vii–viii.
86. Yale JF, Harris SB, Berard L, Groleau M, Javadi P, Stewart J. *A pragmatic self-titration 1 unit/day (INSIGHT) algorithm for insulin glargine 300 U/mL (GLA-300) (Abstract)*. *Diabetes* 2016; 65 (Suppl. 1A): 93–LB.
87. Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M *et al.* Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. *Diabetes Care* 2007; 30(6): 1364–9. Epub 2007/03/27. doi: 10.2337/dc06-1357. PubMed PMID: 17384341.
88. Yki-Järvinen H, Bergenstal R, Ziemien M *et al.* New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). *Diabetes Care* 2014; 37(12): 3235–3243.
89. Zoungas S, Chalmers J, Ninomiya T *et al.* Association of HbA_{1c} levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. *Diabetologia* 2012; 55: 636–643.